Stock's Earning Overview: Delcath Systems, Inc. (NASDAQ:DCTH)

Delcath Systems, Inc.'s (DCTH ), a stock from Drug Delivery Industry, has a value of $0.19 per share, noted a price change of 10.76% in recent trade close.

The firm has noticeable volatility credentials; price volatility of stock was 6.33% for a week and 12.81% for a month.

FT reports, The 24 analysts offering 12 month price targets for WPX Energy Inc have a median target of 18.50, with a high estimate of 24.00 and a low estimate of 13.00. The company beat the analyst EPS Estimate with the difference of $2.63. Currently, the stock has a 1 Year Price Target of $16.

The Company got Initiated by BioLogic Equity Research on 8-Jun-10 to Sell.

Struggling to find a way in profitable zone, the current EPS estimate trend for the next year first quarter was $0 while three months ago that trend was for $-0.04. According to 1 analysts, Price Target for Delcath Systems, Inc. JMP Securities Downgrades the stock to Market Perform on 5/03/13 with no specific Price Target. Beta factor was calculated at 1.63. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). (NASDAQ:DCTH) where 0 analyst have rated the stock as Strong Buy, 1 analysts said it's a Buy, 0 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. While in the same Quarter Previous year, the Actual EPS was $-3.68. Delcath Systems, Inc. (DCTH) has made its way to a 12-month decline of -99.75%. The stock traded with the volume of 27.47 Million shares in the last trading session. The company's market cap is $3.41 Million. The stock has Return on Assets (ROA) of -54.7 percent. The stock price of GALE is moving down from its 20 days moving average with -45.45% and isolated negatively from 50 days moving average with -61.61%. Over the last five days, shares have managed 2.91% gains and now is down -99.14% since hitting its 200-day moving average of $2.0705. Its weekly performance showed downward trend of -10.08 percent. The Return on Investment (ROI) is at -176.9% while it's Return on Equity (ROE) value stands at -221.1%. The short ratio in the company's stock is documented at 0.22 and the short float is around of 36.05%. The Relative Volume value measured for Delcath Systems, Inc. This contrasts with this year Q4 current estimates trend of $-0.09 while for one month was for $-0.12.

Delcath Systems, a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The stock is showing its Operating Margin of 0 percent. Earnings, with 1 analysts believing the company would generate an Average Estimate of $-3.24.

  • Zachary Reyes